Fig. 4
From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
![Fig. 4](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12967-023-04607-4/MediaObjects/12967_2023_4607_Fig4_HTML.png)
A Progression-free survival and B overall survival in patients with type 2 diabetes with increasing or stable blood glucose level during immunotherapy. Increasing level of glucose on treatment was defined as the ratio of blood level at baseline/after 3 months > 1.5